Fredun Pharmaceuticals Ltd Hits All-Time High of Rs 2,145 as Momentum Builds Across Timeframes

Session Recap and Price Action

On 24 Apr 2026, Fredun Pharmaceuticals Ltd closed 1.62% higher, contrasting with the Sensex's decline of 0.99%. The stock has outpaced its Pharmaceuticals & Biotechnology sector by 1.91% today, reflecting sustained buying interest. Over the past week, the stock has surged 16.63%, while the Sensex fell 2.03%, underscoring the stock's relative strength. Notably, the price is trading comfortably above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — reinforcing the bullish technical backdrop. What technical factors are underpinning this sustained momentum in Fredun Pharmaceuticals?

Impressive Long-Term and Short-Term Performance

The stock's performance over various time horizons is eye-catching. It has delivered a staggering 211.77% return over the past year, dwarfing the Sensex's 3.64% decline in the same period. Over three years, the stock has appreciated 146.24%, compared to the BSE500's 28.04%. Even more remarkable is the 10-year return of 15,454.75%, highlighting the company's exceptional growth trajectory. Year-to-date, the stock has gained 35.91%, while the Sensex has dropped 9.77%. This consistent outperformance is supported by a three-month return of 45.25%, again far exceeding the Sensex's negative 5.69%. Such sustained gains reflect both strong fundamentals and positive market sentiment.

Robust Financial Trend and Quarterly Results

Fredun Pharmaceuticals' recent quarterly results reinforce the positive narrative. Net sales for the quarter stood at ₹160.93 crores, marking a robust 56.70% growth. Operating profit (PBDIT) reached a record ₹26.34 crores, while profit before tax excluding other income (PBT less OI) hit a high of ₹14.00 crores. The operating profit margin expanded to 16.37%, signalling improved operational efficiency. Earnings per share (EPS) for the quarter rose to ₹22.20, the highest recorded. However, interest expenses also increased to ₹10.55 crores, which could weigh on net profitability. Despite this, the company has reported positive results for seven consecutive quarters, indicating a sustained upward trajectory. Does the recent surge in interest costs pose a risk to Fredun Pharmaceuticals' profit momentum?

Valuation Metrics and Market Pricing

At the current price of Rs 2,145, Fredun Pharmaceuticals Ltd trades at a price-to-earnings (P/E) ratio of 36x, which is moderate given the company's growth profile. The price-to-book value stands at 7.40x, while the enterprise value to EBITDA ratio is 15.98x. The EV to capital employed ratio is 4.16x, suggesting a fair valuation relative to the company's asset base. The PEG ratio of 0.63x indicates that earnings growth is outpacing the price appreciation, which may appeal to growth-oriented investors. Dividend yield remains minimal at 0.03%, with a payout ratio of just 2.11%, signalling that most earnings are being reinvested. At these valuations, is Fredun Pharmaceuticals still worth holding — or is it time to reassess?

Technical Indicators Confirm Bullish Momentum

The technical landscape for Fredun Pharmaceuticals Ltd is overwhelmingly positive. The overall trend is bullish, having shifted from mildly bullish on 9 Apr 2026 at ₹1,830. Key indicators such as MACD, Bollinger Bands, KST, and Dow Theory all signal bullish momentum on both weekly and monthly charts. RSI currently shows no clear signal, suggesting the stock is not yet overbought. Delivery volumes have surged, with a 74.57% increase on the latest trading day compared to the 5-day average, indicating strong investor participation. Immediate support is near the 52-week low of ₹635.05, while resistance levels are noted at the 20-day moving average of ₹1,817.11 and the 52-week high of ₹1,999.00, which the stock has now surpassed. How sustainable is the current technical momentum in the face of these resistance levels?

Quality Metrics and Capital Structure

Assessing the quality of Fredun Pharmaceuticals Ltd, the company demonstrates excellent long-term growth with a 5-year sales CAGR of 38.09% and EBIT growth of 58.31%. However, capital structure metrics reveal some caution: average net debt to equity stands at 1.03, indicating relatively high leverage, and the average EBIT to interest coverage ratio is a modest 2.58x. Return on capital employed (ROCE) averages 14.74%, which is moderate but not exceptional. The company maintains a low dividend payout ratio of 2.11% and has no promoter share pledging, which is a positive governance signal. Institutional holdings remain low at 3.89%, reflecting limited institutional participation. Does the capital structure and leverage profile temper the otherwise strong growth story?

Promoter Confidence and Stakeholding

Promoter stake in Fredun Pharmaceuticals Ltd has increased by 1.11% over the previous quarter, now standing at 44.17%. This uptick in promoter holding often signals confidence in the company's prospects. The absence of pledged shares further strengthens the governance profile. However, institutional ownership remains modest at 3.89%, which may reflect cautious positioning by larger investors. What does the rising promoter stake indicate about the company's near-term outlook?

Balancing the Bull and Bear Cases

The remarkable price appreciation of Fredun Pharmaceuticals Ltd is supported by strong earnings growth, positive quarterly trends, and a bullish technical setup. The PEG ratio below 1 suggests that earnings growth is still outpacing valuation expansion, which is encouraging. However, the relatively high leverage and rising interest costs introduce a note of caution. Valuation multiples, while not extreme, are elevated compared to historical averages, and the stock is trading well above its 52-week high. This raises the question of whether the current momentum can be sustained or if profit booking may emerge. Should you buy, sell, or hold? With momentum and valuations pulling in opposite directions, no single data point tells the full story — see the complete multi-factor analysis of Fredun Pharmaceuticals Ltd to find out.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →